PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin

MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy

(2013) Julie Halkein et al.   JOURNAL OF CLINICAL INVESTIGATION

Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model

(2011) E. Vercauteren et al.   BLOOD

MicroRNA-21 Exhibits Antiangiogenic Function by Targeting RhoB Expression in Endothelial Cells

(2011) Céline Sabatel et al.   PLoS One

The Antiangiogenic 16K Prolactin Impairs Functional Tumor Neovascularization by Inhibiting Vessel Maturation

(2011) Ngoc-Quynh-Nhu Nguyen et al.   PLoS One

Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis

(2010) G. A. LaRusch et al.   BLOOD

Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth

(2009) Virginie Kinet et al.   CANCER LETTERS

Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents

(2009) Maurizio Zangari et al.   JOURNAL OF CLINICAL ONCOLOGY

Urokinase mediates endothelial cell survival via induction of the X-linked inhibitor of apoptosis protein

(2008) G. W. Prager et al.   BLOOD

Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis

(2008) Khalid Bajou et al.   CANCER CELL

Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients

(2008) Shobha Rani Nalluri et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk

(2007) Argirios E. Tsantes et al.   THROMBOSIS RESEARCH